SENP1 as A Biomarker for the Diagnosis of Cancer: Review of the Science and Published Patents
Jacinta Uzoigwe and Edward R. Sauter
Affiliation: Department of Surgery, University of North Dakota School of Medicine, 501 N. Columbia Rd, Rm 5092, Grand Forks, ND 58202, USA.
Keywords: Bladder cancer, colon cancer prostate cancer, SUMO (small ubiquitin-like modifier) proteins, SENP (SUMO-specific protease)1, Androgen receptor, Histone deacetylase 1, Cyclin D1, Promyelocytic leukemia (PML) protein, Homeodomain-interacting protein kinase 2 (HIPK2), Sirtuin 1 (SIRT 1)
SUMO-specific protease (SENP)1, a member of the SENPs family, has emerged as a potential target to reduce the development of various cancers. Importantly, SENP1 targets essential molecules involved in carcinogenesis. This article provides a review of current understanding of factors targeting and targeted by SENP1 in cancer. It also provides an overview of SENP1 and recently issued US patents that cover various strategies involving the use of SENP1 in the detection of bladder, colon or prostate cancer in a biological sample.
Rights & PermissionsPrintExport